P/E ratio for Avidity Biosciences (RNA)

P/E ratio history for Avidity Biosciences from 2020 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
PTC Therapeutics PTCT	-5.24	-48.16%	🇺🇸 USA
Acorda Therapeutics ACOR	-0.0676	-99.33%	🇺🇸 USA
Sarepta Therapeutics SRPT	-15.6	53.94%	🇺🇸 USA
Catalyst Pharmaceuticals CPRX	19.7	-294.35%	🇺🇸 USA
Fate Therapeutics FATE	-0.7650	-92.44%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA
Pfizer PFE	14.4	-242.16%	🇺🇸 USA
GlaxoSmithKline GSK	9.72	-196.12%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.